Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study – Wall Street Journal
Wall Street Journal Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer StudyWall Street JournalA cancer drug's surprise failure in a clinical trial wiped $20 billion off Bristol-Myers Squibb Co. BMY -15.99 % 's market value Friday, and raised questions about one of the industry's hottest research areas: drugs that harness the body's immune […]
